Allarity Therapeutics Inc (NASDAQ: ALLR) has experienced a rise in its stock price by 1400057 compared to its previous closing price of 0.9. However, the company has seen a gain of 25.88% in its stock price over the last five trading days. globenewswire.com reported 2025-06-11 that TARPON SPRINGS, Fla., June 11, 2025 — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP®) patient selection technology—today announced that Jesper Høiland has been appointed to join the Company’s Board of Directors. He will be replacing Joseph Vazzano, who will resign from the Board effective on June 30, 2025, following his valuable contributions to Allarity’s development over the past two years.
Is It Worth Investing in Allarity Therapeutics Inc (NASDAQ: ALLR) Right Now?
Company’s 36-month beta value is -0.11.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ALLR is 11.53M, and currently, short sellers hold a 9.07% ratio of that floaft. The average trading volume of ALLR on June 25, 2025 was 1.02M shares.
ALLR’s Market Performance
ALLR’s stock has seen a 25.88% increase for the week, with a -1.41% drop in the past month and a 5.00% gain in the past quarter. The volatility ratio for the week is 7.65%, and the volatility levels for the past 30 days are at 5.75% for Allarity Therapeutics Inc The simple moving average for the past 20 days is 18.98% for ALLR’s stock, with a -17.89% simple moving average for the past 200 days.
ALLR Trading at 8.69% from the 50-Day Moving Average
After a stumble in the market that brought ALLR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -90.08% of loss for the given period.
Stock Fundamentals for ALLR
The total capital return value is set at -1.39. Equity return is now at value -383.74, with -112.25 for asset returns.
Currently, EBITDA for the company is -27.24 million with net debt to EBITDA at 1.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.66.
Conclusion
In a nutshell, Allarity Therapeutics Inc (ALLR) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
